{"id":1039034,"date":"2012-05-09T09:14:34","date_gmt":"2012-05-09T09:14:34","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/aviir-laboratories-announce-national-agreement-with-three-rivers-provider-network.php"},"modified":"2024-08-17T16:23:29","modified_gmt":"2024-08-17T20:23:29","slug":"aviir-laboratories-announce-national-agreement-with-three-rivers-provider-network","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pharmacogenomics\/aviir-laboratories-announce-national-agreement-with-three-rivers-provider-network.php","title":{"rendered":"Aviir Laboratories Announce National Agreement with Three Rivers Provider Network"},"content":{"rendered":"<p><p>    IRVINE, Calif., May 7, 2012 \/PRNewswire\/ -- Aviir Diagnostic    Laboratory has entered into a contractual agreement for    ancillary diagnostics laboratory testing as a participating    provider with TRPN and its 10 million lives network.  <\/p>\n<p>    Three Rivers Provider Network (TRPN) was founded in 1996 as a    company that was contracted to provide services for several    major clients. At that time, its clients needed to access a    network that would grant PPO type discounts without incurring    balance billing risks for their members. Over time, given    superior results and the high levels of satisfaction of service    that were achieved, TRPN was prompted by other companies that    focused on group health and workers compensation to perform    similar type services for them.   <\/p>\n<p>    Since that time, TRPN has evolved into the largest and fastest    growing proprietary PPO network in the United States. The TRPN    network is now comprised of more than 600,000 total providers,    including more than 5,000 hospitals and 70,000 ancillary    facilities. Through its clients, approximately 10 million lives    now have access to the TRPN PPO network.  <\/p>\n<p>    Aviir was founded in 2005 by cardiologists and scientists from    the Stanford University School of Medicine to focus on    discovery, development and commercialization of innovative    diagnostic tests.The biotechnology company specializes in    developing proprietary diagnostic teststhat will assist    in identifying patientswho are truly at high risk for the    development of a cardiac event.Aviir's proprietary    MiRisk and TruRisk assessments objectively identify, by a    simple blood draw, individuals who are at a high risk of a    cardiac event over the next five years.Aviir's CLIA    laboratory (Irvine, CA) complements these novel tests with a    wide range of additional tests for risk assessment and    therapeutic monitoring of cardiovascular disease and related    metabolic disorders  including pharmacogenomics and genetic    tests. <a href=\"http:\/\/www.aviir.com\" rel=\"nofollow\">http:\/\/www.aviir.com<\/a>  <\/p>\n<p>    \"There is currently a significant yet unmet clinical need in    the medical community for more effective ways to identify    individuals at high risk of a heart attack who are missed by    current evaluation methods. Providing an accurate assessment of    the patient's overall heart health is the first step in    prevention of cardiovascular disease,\" stated Douglas    Harrington, M.D., Chief Executive Officer of Aviir.  <\/p>\n<p>    \"At Aviir, our ultimate goal is to help physicians identify    those patients who are at serious risk of experiencing a heart    attack but are completely unaware of their precarious    condition. Armed with better information, physicians will be    able to customize individualized treatment plans with the goal    of improving patient therapeutic compliance, reducing their    risk of heart attacks, and decreasing the overall cost of    care,\" Dr. Harrington added.  <\/p>\n<p>    Learn more at <a href=\"http:\/\/www.aviir.com\" rel=\"nofollow\">http:\/\/www.aviir.com<\/a>    Learn more at <a href=\"http:\/\/www.trpnppo.com\" rel=\"nofollow\">http:\/\/www.trpnppo.com<\/a>  <\/p>\n<p>    For more information:    Dina Scaglione    Marketing, Communications Manager    <a href=\"mailto:Dina.Scaglione@aviir.com\">Dina.Scaglione@aviir.com<\/a>  <\/p>\n<\/p>\n<p>View original post here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/aviir-laboratories-announce-national-agreement-224200248.html;_ylt=A2KJjahwNapPNiwAHgL_wgt.\" title=\"Aviir Laboratories Announce National Agreement with Three Rivers Provider Network\" rel=\"noopener\">Aviir Laboratories Announce National Agreement with Three Rivers Provider Network<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> IRVINE, Calif., May 7, 2012 \/PRNewswire\/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostics laboratory testing as a participating provider with TRPN and its 10 million lives network.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pharmacogenomics\/aviir-laboratories-announce-national-agreement-with-three-rivers-provider-network.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246862],"tags":[],"class_list":["post-1039034","post","type-post","status-publish","format-standard","hentry","category-pharmacogenomics"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1039034"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1039034"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1039034\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1039034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1039034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1039034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}